Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 8.01 (Other Events). Phase 2b AZURE-1 met its primary endpoint, supporting brelovitug’s potential as a single-agent HDV therapy.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 2b AZURE-1 met its primary endpoint, supporting brelovitug’s potential as a single-agent HDV therapy
- Virologic response reached 100% with 300 mg QW and 75% with 900 mg Q4W versus 0% delayed treatment
- Composite response reached 45% and 35%, with p-values of 0.003 and 0.024, respectively
- Safety appeared manageable; no treatment discontinuations and no treatment-related serious or Grade 3+ adverse events
- Phase 3 topline data expected in H2 2026, with potential U.S. BLA submission and commercial launch in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.